...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British journal of cancer >Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.
【24h】

Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

机译：放大的端粒酶(hTERT)基因是一个穷人在非小细胞肺癌预后标记。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Telomerase reactivation is a hallmark of human carcinogenesis. Increased telomerase activity may result from gene amplification and/or overexpression. This study evaluates the prognostic value of hTERT gene amplification and mRNA overexpression in 144 resectable non-small-cell lung cancer (NSCLC) specimens. The hTERT gene copy number was assessed by quantitative polymerase chain reaction (qPCR) on laser-capture microdissected tumour cells of 81 tumours, and by fluorescence in situ hybridisation (FISH) on a subset of 59 tumours. hTERT mRNA level was determined by reverse transcription (RT)-qPCR in 130 tumours. In total, 57% of (46 out of 81) primary NSCLC specimens demonstrated hTERT amplification, which was significantly more common (P<0.001) in adenocarcinoma (30 out of 40) than in squamous cell carcinoma (13 out of 37). The hTERT mRNA overexpression was noted in 74% (94 out of 130) of tumours; it was more frequent in squamous cell than in adenocarcinoma (87 vs 68%, P=0.03). Overexpression was significantly associated with amplification (P=0.03), especially in adenocarcinoma. The hTERT gene amplification was prognostic for shorter recurrence-free survival (hazard ratio=2.16, P=0.03). These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC.
机译：端粒酶激活是人类的一个特点致癌作用。从基因扩增和/或结果超表达。hTERT基因扩增和预后的价值在144年可切除的mRNA表达降低非小细胞肺癌(NSCLC)标本。hTERT基因拷贝数被评估定量聚合酶链反应(qPCR)81年laser-capture microdissected肿瘤细胞通过荧光原位肿瘤,杂交(鱼)的一个子集59肿瘤。是由反向hTERT mRNA水平130年转录(RT) -qPCR肿瘤。57%的81年(46)原发性非小细胞肺癌标本证明hTERT放大,这是更常见(P < 0.001)比鳞状腺癌(30 40)细胞癌(13的37)。超表达在74% (94 130)肿瘤;比腺癌(68% vs 87, P = 0.03)。超表达显著相关放大(P = 0.03),特别是在腺癌。预后,缩短recurrence-free生存(风险比= 2.16,P = 0.03)。基因扩增是一个重要的机制在肺腺癌为hTERT超表达和是一个独立的不良预后的标志无病生存期非小细胞肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号